HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
Go back to HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 85.76 +2.17 (2.60%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $83.59 | 52 Week High | $18.39 | |||
| Open | $84.15 | 52 Week Low | $6.96 | |||
| Day High | $86.00 | P/E | N/A | |||
| Day Low | $82.60 | EPS | $-0.58 | |||
| Volume | 2,703,115 | |||||
